WINT Lead Drug Candidates, New Phase 2b Clinical Trial Data, Multiple Programs Focus on Unmet Needs In Cardiogenic Shock & ...

WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced the publication of its SEISMiC Phase 2b trial ...

HU6 is a Controlled Metabolic Accelerator (CMA), a class of therapies specifically designed to reduce body fat while ...

The rumen microbiota—a symbiont to its host and consists of critical functional substances—plays a vital role in the animal ...

Istaroxime is a novel first-in-class investigational therapy that is intended to improve systolic contraction and diastolic relaxation of the heart while also increasing blood pressure and maintaining ...

A calcium transient measurement system utilizing human induced pluripotent stem cell-derived cardiomyocytes reveals the detrimental impact of inflammatory cytokines on cardiomyocyte relaxation and ...

Hypertrophic cardiomyopathy (HCM) is an inherited disorder that may cause disabling and potentially life-threatening symptoms ...

GlobalData’s report assesses the drugs in the Collagenase 3 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

Tirzepatide for diabetes vs long-acting insulins demonstrated superior glycemic control and weight loss compared among adults with type 2 diabetes.

Two new analyses from HELIOS-B answer important questions, but some uncertainties remain, says Julie Rosenthal.

Parisa Zamiri, MD, PhD, and Tom Reilly respectively appointed CMO and CFOAnand Sundaram appointed Vice President MarketingMELBOURNE, Australia ...

USA: A recent study from the EMBARK-HFpEF trial has revealed promising results regarding using mavacamten, a cardiac myosin ...